Free tool
FAERS Monitor: Benicar Hct
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021532 or its brand name (Benicar Hct, Hydrochlorothiazide, Olmesartan Medoxomil). Reports on generic versions are filed under their own applications.
Reports
7,416
Serious
5,143
69% of reports
Hospitalization
3,455
Death reported
178
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- sprue-like enteropathy2,393
- gastrooesophageal reflux disease1,357
- acute kidney injury985
- haemorrhoids974
- weight decreased703
- hiatus hernia668
- constipation641
- large intestine polyp600
- dizziness595
- diverticulitis593
- diarrhoea583
- diverticulum577
- diverticulum intestinal479
- irritable bowel syndrome469
- hypotension423
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 115 |
| 2005 | 176 |
| 2006 | 72 |
| 2007 | 99 |
| 2008 | 123 |
| 2009 | 185 |
| 2010 | 277 |
| 2011 | 246 |
| 2012 | 291 |
| 2013 | 194 |
| 2014 | 234 |
| 2015 | 758 |
| 2016 | 1,190 |
| 2017 | 1,118 |
| 2018 | 1,465 |
| 2019 | 469 |
| 2020 | 110 |
| 2021 | 70 |
| 2022 | 66 |
| 2023 | 58 |
| 2024 | 39 |
| 2025 | 31 |
| 2026 | 30 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,743 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| sprue-like enteropathySignal | 2,393 | 2672.7 | 2539.9 | 3,290,762 |
| diverticulum intestinalSignal | 479 | 348.7 | 318.1 | 147,637 |
| large intestine polypSignal | 600 | 268.8 | 248.0 | 146,054 |
| diverticulumSignal | 577 | 250.4 | 230.7 | 131,536 |
| hiatus herniaSignal | 668 | 154.3 | 143.2 | 96,404 |
| haemorrhoidsSignal | 974 | 149.0 | 140.3 | 136,020 |
| irritable bowel syndromeSignal | 469 | 63.4 | 58.0 | 28,147 |
| diverticulitisSignal | 593 | 62.0 | 57.3 | 34,813 |
| gastrooesophageal reflux diseaseSignal | 1,357 | 48.6 | 46.3 | 62,403 |
| acute kidney injurySignal | 985 | 18.4 | 17.3 | 16,171 |
| constipationSignal | 641 | 8.4 | 7.8 | 4,176 |
| weight decreasedSignal | 703 | 7.2 | 6.7 | 3,758 |
| hypotensionSignal | 423 | 6.0 | 5.5 | 1,767 |
| dizzinessSignal | 595 | 3.4 | 3.1 | 1,021 |
| diarrhoeaSignal | 583 | 2.6 | 2.4 | 571 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.